Aptamer‐PROTAC Conjugates (APCs) for Tumor‐Specific Targeting in Breast Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Aptamer‐PROTAC Conjugates (APCs) for Tumor‐Specific Targeting in Breast Cancer
Authors
Keywords
-
Journal
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-07-09
DOI
10.1002/anie.202107347
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties
- (2021) Peter S. Dragovich et al. JOURNAL OF MEDICINAL CHEMISTRY
- Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy
- (2021) Peter S. Dragovich et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cancer Selective Target Degradation by Folate-Caged PROTACs
- (2021) Jing Liu et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Molecularly Engineering Triptolide with Aptamers for High Specificity and Cytotoxicity for Triple-Negative Breast Cancer
- (2020) Jiaxuan He et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
- (2020) Marı́a Maneiro et al. ACS Chemical Biology
- Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer
- (2020) Francisco J. Cimas et al. Pharmaceutics
- The PROTAC technology in drug development
- (2019) Yutian Zou et al. CELL BIOCHEMISTRY AND FUNCTION
- Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer
- (2019) Patrick R. Halliday et al. Current Oncology Reports
- Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: Recent progress and future challenges
- (2019) Scott D. Edmondson et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Clinical promise of next-generation complement therapeutics
- (2019) Dimitrios C. Mastellos et al. NATURE REVIEWS DRUG DISCOVERY
- Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs
- (2019) Patrick Pfaff et al. ACS Central Science
- Degradation of proteins by PROTACs and other strategies
- (2019) Yang Wang et al. Acta Pharmaceutica Sinica B
- Therapeutic applications of AS1411 aptamer, an update review
- (2019) Rezvan Yazdian-Robati et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Aptamer-Functionalized DNA Origami for Targeted Codelivery of Antisense Oligonucleotides and Doxorubicin to Enhance Therapy in Drug-Resistant Cancer Cells
- (2019) Qingshan Pan et al. ACS Applied Materials & Interfaces
- PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery
- (2018) Shanshan Gu et al. BIOESSAYS
- Challenges and new frontiers in analytical characterization of antibody-drug conjugates
- (2018) Anil Wagh et al. mAbs
- Structural basis of PROTAC cooperative recognition for selective protein degradation
- (2017) Morgan S Gadd et al. Nature Chemical Biology
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Influence of Molecular size on the clearance of antibody fragments
- (2017) Zhe Li et al. PHARMACEUTICAL RESEARCH
- A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer
- (2017) Fangfei Li et al. Nature Communications
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- Aptamers as targeted therapeutics: current potential and challenges
- (2016) Jiehua Zhou et al. NATURE REVIEWS DRUG DISCOVERY
- Dual-channel NIR activatable theranostic prodrug for in vivo spatiotemporal tracking thiol-triggered chemotherapy
- (2016) Mingzhou Ye et al. Chemical Science
- A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma
- (2013) Jonathan E. Rosenberg et al. INVESTIGATIONAL NEW DRUGS
- Plasma Membrane Nucleolin Is a Receptor for the Anticancer Aptamer AS1411 in MV4-11 Leukemia Cells
- (2009) S. Soundararajan et al. MOLECULAR PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started